


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (canceled)

Claim 2. (currently amended) A compound of the formula



wherein R_1 is independently selected from the group consisting of H; alkyl; substituted alkyl; alkoxy; halo; substituted alkoxy; hydroxy; trifluoralkyl; nitro; amino; alkylamino; cycloalkylamino; cyano; carboxy; cycloalkyl; phenyl; and substituted phenyl;

R_2 is ~~pyridyl~~ independently selected from the group consisting of H; alkyl; substituted alkyl; halo; heterocycloalkyl; heteroaryl; phenyl; substituted phenyl; naphthyl and substituted naphthyl;

B_1 is hydrogen;

B_2 is hydrogen; or B_1 and/or B_2 are methylene and joined together to form a five or six membered ring;

Y is methylene or carbonyl;


L is selected from the group consisting of

C_{1-8} alkylene; C_{2-10} alkenylene; C_{2-10} alkynylene; C_{3-7} cycloalkylene;


C_{3-7} cycloalkyl C_{1-4} alkylene;

aryl C_{1-4} alkylene;


α -amino C_{4-7} alkylene;




(N-methylene)piperidin-4-yl;




(N-methylene)piperazin-4-yl;




(N-methylene)pyrrolidin-3-yl;



(N-methylene)-4-acetyl-piperidin-4-yl;




and (N-methylene)piperidin-4,4-diyl;




Z is selected from the group consisting of


aryl;




N-sulfonamido;




N-(aryl)sulfonamido;




arylamido;




arylureido;




arylamido:




(aryloxy)carbonylamino;



2,3-dihydro-2-oxo-1*H*-benzimidazol-1-yl;



and 1-aryl-2,3-dihydro-4-oxo-imidazol-5,5-diyl;



R_3 is independently selected from the group consisting of C_{1-6} alkyl; substituted C_{1-8} alkyl; cycloalkyl; substituted cycloalkyl; naphthyl; substituted naphthyl; heteroaryl; and substituted heteroaryl;

R_4 is independently selected from the group consisting of hydrogen;

C₁₋₈alkyl; C₁₋₈alkoxy; substituted C₁₋₈alkoxy; hydroxy; halogen; cyano; nitro; amino; C₁₋₈alkylamino; and C₁₋₈dialkylamino;

R₅ is independently selected from the group consisting of hydrogen; C₁₋₈alkyl; C₁₋₈alkylcarbonyl; aroyl; carbamoyl; amidino; C₁₋₈alkyl; C₁₋₈alkylaminocarbonyl; (arylamino)carbonyl; and arylC₁₋₈ alkylcarbonyl;

R₆ is independently selected from hydrogen and C₁₋₈alkyl;

n is 1-2;

m is 0-3;

p is 1-3; and

q is 1-3;


~~provided that when Z is aryl or heteroaryl, L is (N-methylene)piperazin-4-yl or (N-methylene)-4-acetylpiperidin-4-yl; provided that when L is (N-methylene)piperazin-4-yl, Z is phenyl or naphthyl; when L is (N-methylene)-4-acetylpiperidin-4-yl, Z is phenyl or naphthyl and Y is carbonyl; and when Z is N-sulfonamido or N-(aryl)sulfonamido, L is α -aminoC₄₋₇alkylene, (N-methylene)piperidin-4-yl or (N-methylene)pyrrolidin-3-yl;~~

provided that when L is (N-methylene)piperazin-4-yl, then Z is phenyl or naphthyl; when L is (N-methylene)piperidin-4-yl, then Z is N-sulfonamido, N(aryl)sulfonamido, 2,3-dihydro-2-oxo-1H-benzimidazol-1-yl, benzamido, phenylureido, phenylacetamido or (phenoxy)carbonylamino; when L is (N-methylene)-4-acetyl- piperidin-4-yl, then Z is phenyl or naphthyl and Y is carbonyl; and when L is (N-methylene)piperidin-4,4-diyl, then Z is 1-aryl-2,3-dihydro-4-oxo-imidazol-5,5-diyl and Y is carbonyl;

and enantiomers, diastereomers and pharmaceutically acceptable salts thereof.

Claim 3. (previously presented)
consisting of:


A compound of claim 2 selected from the group




and

Claim 4. (previously presented)
consisting of:

A compound of claim 2 selected from the group



Claim 5. (previously presented) A compound of claim 2 selected from the group consisting of:



and






Docket No. ORT-1588
Serial No. 10/071,483

Claim 6. (canceled)

Claim 7. (canceled)

Claim 8. (previously presented)
consisting of:






A compound of claim 2 selected from the group



and

Claim 9. (previously presented)
consisting of:

A compound of claim 2 selected from the group




and

Claim 10. (canceled)

Claim 11. (canceled)

Claim 12. (withdrawn)
of:

A compound of claim 2 selected from the group consisting



and

Claim 13. (canceled)

Claim 14. (canceled)

Claim 15. (canceled)

Claim 16. (canceled)

Claim 17. (currently amended) A method of treating disorders and diseases associated with NPY receptor subtype 5 selected from the group consisting of eating disorders, obesity, diabetes, memory loss, epileptic seizures, migraine, sleep disturbances, pain, sexual.reproductive disorders, depression and anxiety comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of claim 2.

Claim 18. (currently amended) A pharmaceutical composition for the treatment of diseases or disorders associated with the NPY Y5 receptor subtype selected from the group consisting of eating disorders, obesity, diabetes, memory loss, epileptic seizures, migraine, sleep disturbances, pain, sexual.reproductive disorders, depression and anxiety comprising a therapeutically effective amount of a compound of claim 2 and a pharmaceutically acceptable carrier.

Claim 19. (canceled)